Expression of long non-coding RNA CRNDE in glioma and its correlation with tumor progression and patient survival

• Published in: European review for medical and pharmacological sciences Vol. 20; no. 19; p. 3992
• Main Authors: Jing, S-Y, Lu, Y-Y, Yang, J-K, Deng, W-Y, Zhou, Q, Jiao, B-H
• Format: Journal Article
• Language: English
• Published: Italy 01-10-2016
• Subjects: Biomarkers, Tumor - genetics; Brain Neoplasms - genetics; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Glioma - genetics; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local - genetics; Prognosis; RNA, Long Noncoding - genetics
• ISSN: 2284-0729

Long non-coding RNAs (lncRNAs) CRNDE has been identified as a tumor oncogene in glioma. However, its clinical significance and prognostic value in glioma have not been investigated until now. The aim of this study was to explore CRNDE expression levels and evaluated its clinical significance in glioma patients.
Expression levels of lncRNA CRNDE in 164 glioma specimens were determined by quantitative real-time PCR (qRT-PCR). The chi-square test was used to explore CRNDE expression with respect to clinicopathological parameters. The overall survival was analyzed by log-rank test, and survival curves were plotted according to Kaplan-Meier. Univariate and multivariate analyses were performed to analyze the prognostic significance of CRNDE expression.
Compared with nonneoplastic brain tissues, the expression level of CRNDE was significantly increased in glioma tissues (p < 0.01). CRNDE upregulation was correlated with larger tumor size (p = 0.011), higher WHO grade (p = 0.001), and recurrence (p = 0.008). Also, survival analysis proved that up-regulated CRNDE expression was associated with poor overall survival of glioma patients (p < 0.001). The multivariate Cox regression analysis indicated that CRNDE expression was an independent prognostic factor for overall survival.
These results indicated that lncRNA CRNDE was associated with tumor progression and could be an independent prognostic factor for glioma patients.